The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

With vision loss due to diabetes emerging as one of the most serious yet overlooked complications in India, Firstpost brings ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

Diabetic retinopathy (DR), a serious eye condition caused by damage to the blood vessels in the retina—the light-sensitive tissue at the back of the eye—is a major public health concern in India. This ...

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

India holds the unenviable position of being home to the world’s largest diabetic population, with nearly 100 million ...

Diabetes affects more than 101 million people in India today. The number is estimated to reach 125 million by the year 2045.

The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...